AXSM Axsome Therapeutics Inc
Company Analysis
Latest News
🔴 Axsome Therapeutics Inc is trading 35.3% down today with no clear company-specific catalyst
Axsome Therapeutics Inc is trading at $163.19 (-35.28%) in after-hours trading following a sharp drop from the regular-session close, despite no immediate...
🟢 Axsome Therapeutics Inc is trading 8.5% up today after presenting new data at SLEEP 2026 conference
Axsome Therapeutics Inc is trading 8.5% up at $275.00 in pre-market, extending a strong multi-day uptrend. • The company announced new data presentations on...
Axsome Therapeutics Price Target Raised to $380, Forecasting $6B Auvelity Sales
Jefferies raised its price target for Axsome Therapeutics (NASDAQ: AXSM) to $380 from $275. The firm maintained its Buy rating, noting significant upside from...
🟢 Axsome Therapeutics Inc is trading 4% up today on pipeline optimism and bullish analyst views
Axsome Therapeutics Inc is trading 4% up today at $256.20 as investors lean into recent positive analyst sentiment and optimism surrounding the company's CNS...
Axsome Shareholders Approve All Proposals at 2026 Annual Meeting
Axsome Therapeutics announced the official results from its 2026 Annual Meeting of Stockholders held on June 5, 2026. All three proposals submitted to a vote...
Axsome Therapeutics Adopts New Executive Severance and Change in Control Plan
Axsome Therapeutics announced the adoption of a new Executive Severance and Change in Control Plan, effective June 5, 2026. The plan standardizes severance...
🟢 Axsome Therapeutics Inc is trading 4.19% up
AXSM is trading at $245.00, up 4.19%.
Norges Bank buys $90M Axsome stake, ahead of Alzheimer's drug launch
Norges Bank acquired 495,456 shares of Axsome Therapeutics. The investment is valued at approximately $90.49 million. This purchase gives Norway's central bank...
Axsome Therapeutics targets 2026 Auvelity launch, addressing Alzheimer's agitation
Axsome Therapeutics announced a June 2026 launch of Auvelity for Alzheimer's disease agitation during a Jefferies fireside chat. The company's COO confirmed...
Axsome Prepares Auvelity Alzheimer's Launch, Presents New SYMBRAVO Migraine Data
Axsome Therapeutics is preparing the imminent launch of Auvelity for the treatment of agitation in Alzheimer’s patients. This expansion introduces the product...
🟢 Axsome Therapeutics Inc is trading 4.2% up today amid bullish analyst sentiment and its annual shareholder meeting
Axsome Therapeutics Inc is trading 4.2% up today at $241.19 as investors react positively to the company's 2026 annual shareholder meeting and sustained...
Axsome Settles All SUNOSI Patent Litigation, Delaying Generic Entry Until 2040
Axsome Therapeutics announced it has resolved all patent litigation for its product SUNOSI® (solriamfetol). The settlement agreements with five generic drug...
Axsome Locks Down Its Sleep Drug From Generics Until 2040 — But Can It Grow Fast Enough to Justify the Bet?
Shares of Axsome Therapeutics surged 6.9% to $237.40 after the company announced it has now settled all outstanding patent litigation over its wakefulness...
🟢 Axsome Therapeutics Inc is trading 7.1% up today after settling all SUNOSI patent litigation
Axsome Therapeutics Inc is trading 7.1% up at approximately $237–238 in pre-market trading after announcing a comprehensive settlement of all SUNOSI...
🟢 Axsome Therapeutics Inc is trading 7.1% up today after settling SUNOSI® patent litigation
Axsome Therapeutics Inc is trading 7.1% up at $238.00 in pre-market action after the company announced a significant legal development. * The company...
🔴 Axsome Therapeutics Inc is trading 4.5% down today in a likely profit-taking pullback
Axsome Therapeutics Inc is trading 4.5% down today at $219.83 as investors appear to lock in profits following a strong run driven by earlier positive...
🔴 Axsome Therapeutics Inc is trading 4.2% down today in a likely profit-taking move
Axsome Therapeutics Inc is trading 4.2% down at $220.64 as the stock gives back a portion of its recent gains following a period of positive regulatory and...